PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Hepatic Impairment Study for PF-04965842.
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03626415
- Locations
- 🇺🇸
Prism Clinical Research, LLC, Saint Paul, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03627754
- Locations
- 🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Bioequivalence (BE) Study Comparing Fluconazole 150mg Capsule Manufactured in China and in France
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT03621072
- Locations
- 🇨🇳
Wuxi People's Hospital//Phase One Unit, Wuxi, Jiangsu, China
A Study of Benzathine Benzylpenicillin Intramuscular Injection in Japanese Healthy Subjects
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT03612557
- Locations
- 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan
A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)
- Conditions
- Healthy Females
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2019-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03608241
- Locations
- 🇺🇸
Quotient Sciences-Miami, Inc., Miami, Florida, United States
🇺🇸Quotient Sciences, Coral Gables, Florida, United States
Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects
- Conditions
- Healthy
- Interventions
- Biological: PF-06946860Other: Placebo
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 63
- Registration Number
- NCT03599063
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Glasdegib Renal Impairment Study
- Conditions
- Renal Impairment
- Interventions
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03596567
- Locations
- 🇺🇸
Prism Clinical Research LLC, Saint Paul, Minnesota, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT03597217
- Locations
- 🇯🇵
P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan
Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03593707
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
- Conditions
- Hemophilia BHemophilia A
- Interventions
- Drug: Standard of Care FIX Replacement therapyDrug: Standard of Care FVIII Replacement therapy
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 213
- Registration Number
- NCT03587116
- Locations
- 🇮🇹
UOC Medicina Interna - Malattie Emorragiche e Trombotiche, Napoli, Naples, Italy
🇺🇸Stanford Health Care, Stanford, California, United States
🇧🇪Cliniques universitaires Saint-Luc/Unité d'Hématology et Hémostase, Brussels, Belgium